Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients

被引:84
作者
Williams, BA
Sugimura, H
Endo, C
Nichols, FC
Cassivi, SD
Allen, MS
Pairolero, PC
Deschamps, C
Yang, P
机构
[1] Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Ctr Canc, Coll Med, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Coll Med, Div Gen Thorac Surg, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Coll Med, Div Epidemiol, Rochester, MN 55905 USA
[4] Mayo Clin & Mayo Fdn, Coll Med, Div Biostat, Rochester, MN 55905 USA
关键词
D O I
10.1016/j.athoracsur.2005.09.020
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Survival after recurrence subsequent to complete resection of nonsmall-cell lung cancer (NSCLC) has been considered a multifactorial process dependent on demographic, clinical, biological, and treatment characteristics. This study sought to quantify the prognostic effects of these characteristics on postrecurrence survival. Methods. Three hundred ninety NSCLC patients who underwent complete resection and subsequently had recurrent cancer were studied. The associations between characteristics of both the initial and recurrent disease with postrecurrence survival were evaluated by Cox proportional hazards models. A multivariable Cox model determined those factors most strongly associated with postrecurrence survival. A simple algorithm based on this model facilitates estimating risk of postrecurrence mortality, as quantified by risk score points. Results. The factors most strongly associated with postrecurrence survival were performance status at recurrence (3 or 4, 4.2 points; 2, 2.8 points; and 1, 1.5 points), symptoms at recurrence (3.6 points), liver recurrence (2.3 points), initial lung cancer stage IIB or worse (1.8 points), and multiple recurrences (1.0 points). Based on these factors, patients were stratified as low risk (4.0 or fewer total points), moderate-low risk (4.1 to 6.1 points), moderate-high risk (6.1 to 8.0 points), and high risk (more than 8.0 points), with 12-month survival of 75%, 51%, 25%, and 9%, respectively. Postrecurrence survival was significantly different across groups (p < 0.01). Conclusions. The proposed prediction instrument offers clinicians a succinct tool for rapidly evaluating mortality risk after recurrence. The characteristics comprising this instrument can be easily ascertained and measured, making it of potential clinical value.
引用
收藏
页码:1021 / 1027
页数:7
相关论文
共 37 条
[1]   Disease recurrence after resection for stage I lung cancer [J].
AlKattan, K ;
Sepsas, E ;
Fountain, SW ;
Townsend, ER .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1997, 12 (03) :380-384
[2]   Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small-cell lung carcinomas: Are these carcinomas candidates for video-assisted lobectomy? [J].
Asamura, H ;
Nakayama, H ;
Kondo, H ;
Tsuchiya, R ;
Shimosato, Y ;
Naruke, T .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1996, 111 (06) :1125-1134
[3]   Patterns of recurrence and outcome for patients with clinical stage II non-small-cell lung cancer [J].
Baldini, EH ;
DeCamp, MM ;
Katz, MS ;
Berman, SM ;
Swanson, SJ ;
Mentzer, SJ ;
Bueno, R ;
Sugarbaker, DJ .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (01) :8-14
[4]   External validation is necessary in, prediction research: A clinical example [J].
Bleeker, SE ;
Moll, HA ;
Steyerberg, EW ;
Donders, ART ;
Derksen-Lubsen, G ;
Grobbee, DE ;
Moons, KGM .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2003, 56 (09) :826-832
[5]   Prognostic factors in non-small cell lung cancer - A decade of progress [J].
Brundage, MD ;
Davies, D ;
Mackillop, WJ .
CHEST, 2002, 122 (03) :1037-1057
[6]   Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution [J].
Buccheri, G ;
Ferrigno, D ;
Tamburini, M .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (07) :1135-1141
[7]   LOCAL AND/OR DISTANT RECURRENCES IN T1-2/NO-1 NON-SMALL-CELL LUNG-CANCER [J].
CANGEMI, V ;
VOLPINO, P ;
DANDREA, N ;
PUOPOLO, M ;
FABRIZI, S ;
LONARDO, MT ;
PIAT, G .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1995, 9 (09) :473-478
[8]   Prediction of survival in terminal cancer patients in Taiwan: Constructing a prognostic scale [J].
Chuang, RB ;
Hu, WY ;
Chiu, TY ;
Chen, CY .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2004, 28 (02) :115-122
[9]   Radiation therapy for intrathoracic recurrence of non-small cell lung cancer [J].
Emami, B ;
Graham, MV ;
Deedy, M ;
Shapiro, S ;
Kucik, N .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1997, 20 (01) :46-50
[10]  
HARPOLE DH, 1995, CANCER RES, V55, P51